157 related articles for article (PubMed ID: 18855724)
1. CXCR4 receptor as a promising target for oncolytic drugs.
Lavrovsky Y; Ivanenkov YA; Balakin KV; Medvedeva DA; Ivachtchenko AV
Mini Rev Med Chem; 2008 Oct; 8(11):1075-87. PubMed ID: 18855724
[TBL] [Abstract][Full Text] [Related]
2. The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection.
Patrussi L; Baldari CT
Curr Med Chem; 2011; 18(4):497-512. PubMed ID: 21143114
[TBL] [Abstract][Full Text] [Related]
3. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
5. The chemokine receptor CXCR4 as a therapeutic target for several diseases.
Tamamura H; Tsutsumi H; Fujii N
Mini Rev Med Chem; 2006 Sep; 6(9):989-95. PubMed ID: 17017998
[TBL] [Abstract][Full Text] [Related]
6. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
[TBL] [Abstract][Full Text] [Related]
7. Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.
Xu D; Li R; Wu J; Jiang L; Zhong HA
Curr Top Med Chem; 2016; 16(13):1441-51. PubMed ID: 26369824
[TBL] [Abstract][Full Text] [Related]
8. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
Zhou W; Guo S; Liu M; Burow ME; Wang G
Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
[TBL] [Abstract][Full Text] [Related]
9. The role of CXCL12 in tumor microenvironment.
Meng W; Xue S; Chen Y
Gene; 2018 Jan; 641():105-110. PubMed ID: 29017963
[TBL] [Abstract][Full Text] [Related]
10. Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates.
Khan A; Greenman J; Archibald SJ
Curr Med Chem; 2007; 14(21):2257-77. PubMed ID: 17896975
[TBL] [Abstract][Full Text] [Related]
11. Xanthohumol, a prenylated chalcone derived from hops, suppresses cancer cell invasion through inhibiting the expression of CXCR4 chemokine receptor.
Wang Y; Chen Y; Wang J; Chen J; Aggarwal BB; Pang X; Liu M
Curr Mol Med; 2012 Feb; 12(2):153-62. PubMed ID: 22172099
[TBL] [Abstract][Full Text] [Related]
12. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases.
Gil M; Seshadri M; Komorowski MP; Abrams SI; Kozbor D
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):E1291-300. PubMed ID: 23509246
[TBL] [Abstract][Full Text] [Related]
13. The good and bad faces of the CXCR4 chemokine receptor.
Teixidó J; Martínez-Moreno M; Díaz-Martínez M; Sevilla-Movilla S
Int J Biochem Cell Biol; 2018 Feb; 95():121-131. PubMed ID: 29288743
[TBL] [Abstract][Full Text] [Related]
14. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA; Stewart DJ; Wald O; Peled A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
[TBL] [Abstract][Full Text] [Related]
15. Halting metastasis through CXCR4 inhibition.
Ramsey DM; McAlpine SR
Bioorg Med Chem Lett; 2013 Jan; 23(1):20-5. PubMed ID: 23211868
[TBL] [Abstract][Full Text] [Related]
16. Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma.
Albert S; Riveiro ME; Halimi C; Hourseau M; Couvelard A; Serova M; Barry B; Raymond E; Faivre S
Head Neck; 2013 Dec; 35(12):1819-28. PubMed ID: 23468253
[TBL] [Abstract][Full Text] [Related]
17. Polyfunctionality of the CXCR4/CXCL12 axis in health and disease: Implications for therapeutic interventions in cancer and immune-mediated diseases.
Britton C; Poznansky MC; Reeves P
FASEB J; 2021 Apr; 35(4):e21260. PubMed ID: 33715207
[TBL] [Abstract][Full Text] [Related]
18. CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis.
Mortezaee K
Life Sci; 2020 May; 249():117534. PubMed ID: 32156548
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic knockout of CXCR4 by a novel recombinant protein TAT/54R/KDEL inhibits tumors metastasis.
Ma WF; Du J; Fu LP; Fang R; Chen HY; Cai SH
Mol Cancer Res; 2009 Oct; 7(10):1613-21. PubMed ID: 19825996
[TBL] [Abstract][Full Text] [Related]
20. Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion.
Miyanishi N; Suzuki Y; Simizu S; Kuwabara Y; Banno K; Umezawa K
Biochem Biophys Res Commun; 2010 Dec; 403(1):154-9. PubMed ID: 21059341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]